It comes down to competence.
Firstly it was a big $40 mio deal with a deposit to be paid of $1mio expected "soon"
Then it was "by the end of November"
Then the "beginning of 2018"
Then it was that the samples were "damaged"
Then it was that a "testing program" is required
Then you hear that they are not using MGC product in the formulation and may start to use it by June 2018.
Then an ann is made about cannepil being cleared for distribution, then its not or has not had a final clearance for sale.
Now we only have an "intrim GMP" with no idea when a full one is to be granted.
Then the Malta deal. Malta is rife with corruption, and I'm still unclear as to whether the deal MGC signed that allows growing and production has actually been passed into legislation.
Is it any wonder the SP is slipping.
MXC Price at posting:
7.9¢ Sentiment: None Disclosure: Held
